<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35487644</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1757-790X</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>15</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
              <Day>29</Day>
            </PubDate>
          </JournalIssue>
          <Title>BMJ case reports</Title>
          <ISOAbbreviation>BMJ Case Rep</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Hypercalcaemia to hypocalcaemia: tetany as a side effect of intravenous bisphosphonate treatment.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e249141</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1136/bcr-2022-249141</ELocationID>
        <Abstract>
          <AbstractText>A woman in her 40s with advanced bladder cancer was admitted to hospital with hypercalcaemia of malignancy. Initially, she presented with non-specific symptoms of malaise, fatigue and general deterioration. She was treated with intravenous fluids and zoledronic acid in order to bring her calcium levels down, but subsequently developed significant hypocalcaemia. This manifested as tetany in the hands in the form of bilateral carpopedal spasm. She also reported perioral paraesthesia. Bloods during her admission revealed deranged electrolytes, and her vitamin D level was on the lower scale of normal (25 nmol/L). The patient's symptoms improved with electrolyte replacement and oral baclofen for her symptomatically distressing wrist and hand muscle spasms. This case report is a reminder that bisphosphonates can cause significant hypocalcaemia with symptoms of tetany, even when they are given for initial hypercalcaemia. Baclofen worked well to improve symptoms.</AbstractText>
          <CopyrightInformation>© BMJ Publishing Group Limited 2022. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Bounds</LastName>
            <ForeName>Lauren</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Palliative Care Department, Velindre University NHS Trust, Cardiff, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McGrath</LastName>
            <ForeName>Felix</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Palliative Care Department, Velindre University NHS Trust, Cardiff, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Taubert</LastName>
            <ForeName>Mark</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-0454-5609</Identifier>
            <AffiliationInfo>
              <Affiliation>Palliative Care Department, Velindre University NHS Trust, Cardiff, UK mtaubert@doctors.org.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>29</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>BMJ Case Rep</MedlineTA>
        <NlmUniqueID>101526291</NlmUniqueID>
        <ISSNLinking>1757-790X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>H789N3FKE8</RegistryNumber>
          <NameOfSubstance UI="D001418">Baclofen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001418" MajorTopicYN="N">Baclofen</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004164" MajorTopicYN="N">Diphosphonates</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006934" MajorTopicYN="Y">Hypercalcemia</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006996" MajorTopicYN="Y">Hypocalcemia</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013746" MajorTopicYN="Y">Tetany</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Calcium and bone</Keyword>
        <Keyword MajorTopicYN="N">Cancer - see Oncology</Keyword>
        <Keyword MajorTopicYN="N">Cancer intervention</Keyword>
        <Keyword MajorTopicYN="N">Clinical neurophysiology</Keyword>
        <Keyword MajorTopicYN="N">Malignant disease and immunosuppression</Keyword>
      </KeywordList>
      <CoiStatement>Competing interests: None declared.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pmc-release">
          <Year>2024</Year>
          <Month>4</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
          <Hour>21</Hour>
          <Minute>5</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>4</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35487644</ArticleId>
        <ArticleId IdType="pmc">PMC9058685</ArticleId>
        <ArticleId IdType="doi">10.1136/bcr-2022-249141</ArticleId>
        <ArticleId IdType="pii">15/4/e249141</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Clines GA. Mechanisms and treatment of hypercalcemia of malignancy. Curr Opin Endocrinol Diabetes Obes
2011;18:339–46. 10.1097/MED.0b013e32834b4401</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MED.0b013e32834b4401</ArticleId>
            <ArticleId IdType="pubmed">21897221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>BNF Joint Formulary Committee . British National Formulary (online) London 2021: BMJ Group and Pharmaceutical Press. Available: http://www.medicinescomplete.com [Accessed 23 Jan 2022].</Citation>
        </Reference>
        <Reference>
          <Citation>Electronic Medicine Compendium . Zometa 4mg/5ml concentrate for solution for infusion. electronic medicine compendium website, 2016. Available: https://www.medicines.org.uk/emc/product/11672/smpc#gref [Accessed 23 Jan 2022].</Citation>
        </Reference>
        <Reference>
          <Citation>Parasa M, Saheb SM, Vemuri NN. Cramps and tingling: a diagnostic conundrum. Anesth Essays Res
2014;8:247. 10.4103/0259-1162.134524</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4103/0259-1162.134524</ArticleId>
            <ArticleId IdType="pmc">PMC4173627</ArticleId>
            <ArticleId IdType="pubmed">25886236</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Topakian R, Stieglbauer K, Rotaru J, et al. . Hypocalcemic choreoathetosis and tetany after bisphosphonate treatment. Mov Disord
2006;21:2026–7. 10.1002/mds.21094</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mds.21094</ArticleId>
            <ArticleId IdType="pubmed">16972252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hayes SA, Dowlatshahi S. Beware of bisphosphonate use with the combination of ESRD and vitamin d deficiency. In: Journal of general internal medicine. NEW YORK, USA: SPRINGER, 2018: S472</Citation>
        </Reference>
        <Reference>
          <Citation>Alegbeleye AJ, Mathur R, Sarwar A, et al. . Disproportion between calcium and vitamin D level in vitamin D deficiency induced seizure in an older patient. Inosteoporosis international. 21. London WC1X 8HL, England: Springer London ltd, 2010: 137. https://link.springer.com/article/10.1007%2Fs00198-010-1247-9</Citation>
        </Reference>
        <Reference>
          <Citation>Maalouf NM, Heller HJ, Odvina CV, et al. . Bisphosphonate-Induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract
2006;12:48–53. 10.4158/EP.12.1.48</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP.12.1.48</ArticleId>
            <ArticleId IdType="pubmed">16524863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Papapetrou PD. Bisphosphonate-Associated adverse events. Hormones
2009;8:96–110. 10.14310/horm.2002.1226</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.14310/horm.2002.1226</ArticleId>
            <ArticleId IdType="pubmed">19570737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Baker SB, Worthley LI. The essentials of calcium, magnesium and phosphate metabolism: Part II. disorders.</Citation>
        </Reference>
        <Reference>
          <Citation>Romito JW, Turner ER, Rosener JA, et al. . Baclofen therapeutics, toxicity, and withdrawal: a narrative review. SAGE Open Med
2021;9:2050312121102219710.1177/20503121211022197</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/20503121211022197</ArticleId>
            <ArticleId IdType="pmc">PMC8182184</ArticleId>
            <ArticleId IdType="pubmed">34158937</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
